Boston, MA, October 26 2020 (Seeking Alpha) — Atea Pharmaceuticals (AVIR) has filed to raise $253 million in an IPO of its common stock, according to an S-1 registration statement.The company is a clinical stage biopharma developing therapeutics for virus-borne diseases such as Covid-19 and others.
AVIR has produced positive safety trial results but the IPO appears excessively valued, so I’ll pass on the IPO.
Company & Technology
Boston, Massachusetts-based Atea was founded to develop treatments for virus-borne diseases such as Hepatitis C, Dengue and more recently Covid-19.
Management is headed by founder, president, CEO and Chairman Jean-Pierre Sommadossi, Ph.D., who was previously co-founder at Idenix Pharmaceuticals